Several other research analysts also recently commented on DERM. Zacks Investment Research raised Dermira from a hold rating to a buy rating and set a $8.25 price objective for the company in a research note on Wednesday, February 13th. HC Wainwright started coverage on Dermira in a research note on Thursday, February 14th. They issued a buy rating and a $13.00 price objective for the company. Svb Leerink started coverage on Dermira in a research note on Friday, February 22nd. They issued an outperform rating and a $20.00 price objective for the company. Leerink Swann started coverage on Dermira in a research note on Friday, February 22nd. They issued an outperform rating for the company. Finally, ValuEngine raised Dermira from a sell rating to a hold rating in a research note on Tuesday, March 5th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $17.97.
NASDAQ DERM traded down $0.10 during mid-day trading on Thursday, hitting $9.87. The stock had a trading volume of 200 shares, compared to its average volume of 616,946. Dermira has a twelve month low of $6.00 and a twelve month high of $15.48. The company has a debt-to-equity ratio of 4.36, a quick ratio of 6.92 and a current ratio of 7.13. The company has a market cap of $523.26 million, a P/E ratio of -1.89 and a beta of 1.40.
In other Dermira news, insider Eugene A. Bauer sold 35,000 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the sale, the insider now directly owns 43,900 shares of the company’s stock, valued at approximately $658,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.80% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. GYL Financial Synergies LLC purchased a new stake in shares of Dermira in the first quarter valued at $288,000. Jane Street Group LLC lifted its position in shares of Dermira by 200.0% in the first quarter. Jane Street Group LLC now owns 39,493 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 26,328 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Dermira by 32.0% in the first quarter. HighTower Advisors LLC now owns 17,244 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 4,181 shares in the last quarter. Opaleye Management Inc. lifted its position in shares of Dermira by 433.3% in the first quarter. Opaleye Management Inc. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $5,420,000 after acquiring an additional 325,000 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new stake in shares of Dermira in the first quarter valued at $2,033,000. 93.92% of the stock is owned by institutional investors and hedge funds.
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Further Reading: What is the outlook for the FAANG stocks?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.